AMPH 10-Q: SEC filing

Amphastar Pharmaceuticals

Filed with the SEC on · accession 0001297184-26-000053

AMPH filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.

Summary of the filing

Amphastar Pharmaceuticals filed its quarterly 10-Q report for the period ended September 30, 2026, disclosing routine financial statements, segment results, and share repurchase activity under its November 2014 buyback plan.

Key details

FilerAmphastar Pharmaceuticals, Inc.
Supplier/counterpartyNanjing Chengong Pharmaceutical Co. Limited
Supplier/counterpartyNanjing Hanxin Pharmaceutical Technology Co. Ltd

✦ Ask GOAX AI about this filing — what it means for AMPH, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for AMPH?

Click here

Frequently asked questions

What did AMPH file with the SEC on Nov 5, 2026?

AMPH filed a 10-Q (SEC filing). Amphastar Pharmaceuticals filed its quarterly 10-Q report for the period ended September 30, 2026, disclosing routine financial statements, segment results, and share repurchase activity under its November 2014 buyback plan.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

Other AMPH SEC filings

Get alerts when AMPH files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days